Atlas Trials

Moonlight Bio, Inc

1 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Moonlight Bio, Inc

RecordFirmDate
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) (NCT07488923)Moonlight Bio, Inc2026-06-01

Track Moonlight Bio, Inc automatically

Every clearance here is in the API, with alerts when new ones post.